[Current anti-epilepsy drugs].
Iivanainen
M
M
Helsingin yliopiston lastenneurologian klinikka.
Gaily
E
E
D000085:Acetates / Q000008:administration & dosage; D000588:Amines; D000927:Anticonvulsants / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002220:Carbamazepine / Q000008:administration & dosage / Q000031:analogs & derivatives; D003509:Cyclohexanecarboxylic Acids; D004359:Drug Therapy, Combination; D004827:Epilepsy / Q000188:drug therapy*; D000078328:Felbamate; D000077206:Gabapentin; D006801:Humans; D000077213:Lamotrigine; D000078330:Oxcarbazepine; D048448:Phenylcarbamates; D011409:Propylene Glycols / Q000008:administration & dosage; D014227:Triazines / Q000008:administration & dosage; D020888:Vigabatrin; D005680:gamma-Aminobutyric Acid / Q000008:administration & dosage / Q000031:analogs & derivatives
D000085:Acetates; D000588:Amines; D000927:Anticonvulsants; D003509:Cyclohexanecarboxylic Acids; D048448:Phenylcarbamates; D011409:Propylene Glycols; D014227:Triazines; D002220:Carbamazepine; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; D020888:Vigabatrin; D000077213:Lamotrigine; D000078330:Oxcarbazepine; D000078328:Felbamate
Uudet epilepsialääkkeet.